These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 24439479)

  • 21. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
    Toledo JB; Zetterberg H; van Harten AC; Glodzik L; Martinez-Lage P; Bocchio-Chiavetto L; Rami L; Hansson O; Sperling R; Engelborghs S; Osorio RS; Vanderstichele H; Vandijck M; Hampel H; Teipl S; Moghekar A; Albert M; Hu WT; Monge Argilés JA; Gorostidi A; Teunissen CE; De Deyn PP; Hyman BT; Molinuevo JL; Frisoni GB; Linazasoro G; de Leon MJ; van der Flier WM; Scheltens P; Blennow K; Shaw LM; Trojanowski JQ;
    Brain; 2015 Sep; 138(Pt 9):2701-15. PubMed ID: 26220940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.
    Mosconi L; De Santi S; Brys M; Tsui WH; Pirraglia E; Glodzik-Sobanska L; Rich KE; Switalski R; Mehta PD; Pratico D; Zinkowski R; Blennow K; de Leon MJ
    Biol Psychiatry; 2008 Mar; 63(6):609-18. PubMed ID: 17720148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks.
    Kim H; Levine A; Cohen D; Gehrman P; Zhu X; Devanand DP; Lee S; Goldberg TE;
    J Alzheimers Dis; 2022; 87(4):1567-1580. PubMed ID: 35491776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
    Geijselaers SLC; Aalten P; Ramakers IHGB; De Deyn PP; Heijboer AC; Koek HL; OldeRikkert MGM; Papma JM; Reesink FE; Smits LL; Stehouwer CDA; Teunissen CE; Verhey FRJ; van der Flier WM; Biessels GJ;
    J Alzheimers Dis; 2018; 61(1):309-320. PubMed ID: 29154275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
    Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly.
    Slot RER; Kester MI; Van Harten AC; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; van der Flier WM; Veerhuis R
    Neurobiol Aging; 2019 Jul; 79():101-109. PubMed ID: 31029938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults.
    Li G; Shofer JB; Petrie EC; Yu CE; Wilkinson CW; Figlewicz DP; Shutes-David A; Zhang J; Montine TJ; Raskind MA; Quinn JF; Galasko DR; Peskind ER
    Alzheimers Res Ther; 2017 Jul; 9(1):48. PubMed ID: 28673336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.
    Yassine HN; Rawat V; Mack WJ; Quinn JF; Yurko-Mauro K; Bailey-Hall E; Aisen PS; Chui HC; Schneider LS
    Alzheimers Res Ther; 2016 Jun; 8():25. PubMed ID: 27358067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort.
    Law LL; Sprecher KE; Dougherty RJ; Edwards DF; Koscik RL; Gallagher CL; Carlsson CM; Zetterberg H; Blennow K; Asthana S; Sager MA; Hermann BP; Johnson SC; Cook DB; Bendlin BB; Okonkwo OC
    J Alzheimers Dis; 2019; 69(1):111-121. PubMed ID: 30958346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
    J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obstructive Sleep Apnea is Associated With Early but Possibly Modifiable Alzheimer's Disease Biomarkers Changes.
    Liguori C; Mercuri NB; Izzi F; Romigi A; Cordella A; Sancesario G; Placidi F
    Sleep; 2017 May; 40(5):. PubMed ID: 28329084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex differences in CSF biomarkers vary by Alzheimer disease stage and
    Babapour Mofrad R; Tijms BM; Scheltens P; Barkhof F; van der Flier WM; Sikkes SAM; Teunissen CE
    Neurology; 2020 Oct; 95(17):e2378-e2388. PubMed ID: 32788242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.
    Risacher SL; Kim S; Nho K; Foroud T; Shen L; Petersen RC; Jack CR; Beckett LA; Aisen PS; Koeppe RA; Jagust WJ; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
    Alzheimers Dement; 2015 Dec; 11(12):1417-1429. PubMed ID: 25960448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study.
    Li QY; Hu HY; Zhang GW; Hu H; Ou YN; Huang LY; Wang AY; Gao PY; Ma LY; Tan L; Yu JT
    Alzheimers Res Ther; 2024 Feb; 16(1):28. PubMed ID: 38321520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.